Alltracel's Nanopeutics Subsidiary Agrees Exclusive Nanotechnology Development Partnership With a Global Leader IN Professional Woundcare

Partner Funding Development Costs and Additional Licence Fee

Successful Development Will Lead to Exclusive Global Royalty Bearing

Licence and Supply Agreement

DUBLIN, Ireland and LIBEREC, Czech Republic, November 14

Nov 14, 2006, 00:00 ET from Alltracel Pharmaceuticals Plc.

/PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., ("Alltracel", or
 "the Company"),(LSE: AP) the Medical Technology Company focused on the
 Woundcare, Oralcare and Cardiovascular Health markets today announces that
 Nanopeutics(TM) s.r.o., ("Nanopeutics"), the specialist subsidiary
 dedicated to the commercialisation of Nanospider(TM) technology for the
 global woundcare market, has signed an exclusive partnership agreement with
 a world leader in the professional woundcare market.
     The agreement is for an exclusive six month period and is focused on
 the development of a range of nanofibre based professional wound care
 technologies and products. Under the agreement, all development work and
 associated costs will be paid for by the Nanopeutics(tm) partner as well as
 payment of an associated undisclosed licence fee for the six months
 exclusivity period.
     The successful conclusion to the development work will lead to an
 exclusive global royalty bearing licence and supply agreement for
 Nanospider(TM) based technology and specialist products for the
 professional woundcare and potential related markets.
     The agreement does not cover the consumer wound care market.
     Alltracel Pharmaceutical's CEO, Tony Richardson, commented:
     "This development agreement represents a significant technological
 breakthrough into the EUR10 billion professional woundcare sector for
 Alltracel. For the past year we have been working with a number of
 potential woundcare partners in successfully testing a range of advanced
 woundcare product concepts. This significant global partnership agreement,
 signed today by our specialist Nanopeutics(TM) subsidiary has been
 facilitated by that validation work.
     A specific product and technology development effort is now in place
 both at Nanopeutics(TM) and at the market leading partner, for the
 development of a range of advanced nanofibre based product applications and
 technologies and we look forward to further news in this regard in the next
 six months
     Commercialising Nanospider(TM) technology in the global woundcare
 market via Nanopeutics(TM) remains a priority business development focus
 for Alltracel, and outside of this significant development for the
 professional market, Nanopeutics(TM) is now in discussions with a number of
 other woundcare companies for consumer woundcare and other applications."
     Notes to Editors:
     Nanopeutics(TM) s.r.o. ("Nanopeutics") ( is the
 specialist Alltracel subsidiary formed as part of a joint venture with
 Elmarco s.r.o. dedicated to the commercialisation of Nanospider(TM)
 technology for the global professional and consumer woundcare markets.
     Nanopeutics, headquartered in Liberec in the Czech Republic and
 operating internationally, has been licensed and/or assigned the relevant
 woundcare and Nanospider(TM) intellectual property and patents.
 Nanospider(TM) is the novel patented process for spinning polymers into
 nano-scale fibres for a range of industrial, chemical, micro-electronic and
 bio-medical applications. The Nanospider(TM) technology has been recognised
 internationally as a major breakthrough in the mass production of nanofibre
     Alltracel (AIM: AP.L) ( Alltracel Pharmaceuticals Plc
 ("Alltracel") is a Medical Technology Company focused on the Woundcare,
 Oralcare and Cardiovascular Health markets.
     With corporate headquarters in Dublin, Ireland; Alltracel has a
 commercial office in London, England; R&D subsidiary in the Czech Republic
 and manufacturing facilities in Shenzhen, China. Alltracel was founded in
 1996 and listed on London's Alternative Investment Market in July 2001.
     Alltracel has a number of patents in the areas of polysaccharide
 manipulation and PTFE processes and products as well as a significant
 collaborative R&D programme in place focused on its markets.
     In the consumer Woundcare market m-doc(TM) (Micro Dispersed Oxidized
 Cellulose; ( is the trading name given to Alltracel's
 patented technology which is proven as an effective and efficient
 haemostatic (blood-stopping) agent and is currently being marketed as the
 leading stops bleeding ingredient brand within recognized woundcare, and
 relevant first-aid brands worldwide. Alltracel's specialist Nanotechnology
 subsidiary Nanopeutics(TM) is headquartered in Liberec in the Czech
 Republic and is dedicated to the commercialisation of Nanospider(TM)
 technology for the global professional and consumer woundcare markets.
     Within the Cardiovascular Health market Alltracel
 ( has developed a novel bioactive compound that,
 following over two years of scientific research including in vitro,
 pre-clinical and clinical trials, indicates cardiovascular health (CVH)
 benefits on its own and in combination with existing CVH products.
     The end result is a pioneering, value-adding bioactive that can enhance
 and differentiate current cardiovascular health products and that can add
 benefit to current non-health benefiting nutritious finished foods.
     m-doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.
     Nanospider(TM) and Nanopeutics(TM) are trademarks controlled by
 Nanopeutics s.r.o.
     For Further Information Contact:
     Dublin: Denise Cronin
     Alltracel: +353-1-235-2162
     London: Deborah Scott
     Financial Dynamics: +44-0207-831-3113
     New York: Sean Leous
     Financial Dynamics: +1-212-850-5626

SOURCE Alltracel Pharmaceuticals Plc.